Advertisement
Organisation › Details
Microbiome Diagnostics Partners (MDP)
Enterome SA, a pioneer of innovative therapies for microbiome-related diseases, and Nestlé Health Science, announce the joint creation of Microbiome Diagnostics Partners (MDP). This company will bring together complementary, world-leading platforms and capabilities enabling the discovery and development of innovative diagnostics through to commercialization in multiple diseases areas, including inflammatory bowel diseases (IBD) and liver diseases. MDP will be a 50/50 joint venture between Enterome and Nestlé Health Science. Enterome will contribute its current microbiome diagnostic programs and intellectual property (IP) derived from its unique microbiome-based platform for the development of diagnostics in all therapeutic areas except immuno-oncology. Prometheus Laboratories (a Nestlé Health Science Company) will contribute its diagnostics development and commercialization expertise. Nestlé Health Science will invest €20 million in return for its 50% stake in MDP and exclusive commercialization options on the initial programs. In addition to this investment, MDP will receive further milestone payments linked to the success of clinical and commercial activities. MDP will be governed by a Board, with Pierre Belichard, CEO of Enterome becoming Chairman. Warren Cresswell, General Manager and Head of Prometheus Diagnostics, will become a Board member of MDP and assume the role of MDP CEO. Initially, MDP will focus on developing diagnostics for the assessment and management of IBD based on Enterome’s IBD110 microbiome-derived mucosal healing biomarker and on the development of diagnostic products for progressive liver diseases [non-alcoholic fatty liver disease, (NAFLD), including non-alcoholic steatohepatitis (NASH)] based on Enterome’s MET210 biomarker. Prometheus will provide its serum-based biomarkers to both development programs. *
Start | 2017-07-11 established jv 50/50 | |
Group | Nestlé (Group) | |
Industry | diagnostics (medical/biological) | |
Industry 2 | microbiomics | |
Person | Cresswell, Warren (Nestlé 201707 General Manager + Head of Prometheus Diagnostics + CEO of MDP) | |
Person 2 | Belichard, Pierre (Enterome 201203 CEO) | |
City | n. a. | |
Address record changed: 2017-07-19 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Enterome S.A.. (7/11/17). "Press Release: Enterome and Nestlé Health Sciences Launch New Diagnostics Company". Paris. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Nestlé (Group)
- [1] Recipharm AB. (11/21/23). "Press Release: Marc Funk to Transition to Recipharm's Board of Directors; Greg Behar Appointed New CEO; Inhaled Business to Standalone in 2024"....
- [2] Enterome S.A.. (7/18/22). "Press Release: Enterome Signs Major Strategic R&D Collaboration with Nestlé Health Science to Develop and Commercialize New AllerMimics and EndoMimics Immunotherapies for Food Allergies and Inflammatory Bowel Disease". Paris....
- [3] Seres Therapeutics, Inc.. (7/1/21). "Press Release: Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement". Cambridge, MA & Lausanne....
- [4] ECBF Management GmbH. (12/15/20). "Press Release: The European Circular Bioeconomy Fund Welcomes Nestlé as an Investor to Accelerate Sustainable Innovation in Europe". Luxembourg....
- [5] Aimmune Therapeutics, Inc.. (8/31/20). "Press Release: Aimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science". Brisbane, CA....
- [6] Seres Therapeutics, Inc.. (8/17/20). "Press Release: Seres Therapeutics, Inc. Announces Closing of Public Offerings of 12,075,000 Shares of Common Stock". Cambridge, MA....
- [7] Aimmune Therapeutics, Inc.. (2/5/20). "Press Release: Aimmune Therapeutics Announces Additional $200 Million Equity Investment by Nestlé Health Science". Brisbane, CA....
- [8] Aimmune Therapeutics, Inc.. (3/25/19). "Press Release: European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary Endpoint. Company Intends to Submit European MAA in Mid-2019". Brisbane, CA....
- [9] Seres Therapeutics, Inc.. (3/6/19). "Press Release: Seres Therapeutics Reports Fourth Quarter and Full Year Financial Results and Provides Operational Updates". Cambridge, MA....
- [10] Aimmune Therapeutics, Inc.. (2/28/19). "Press Release: Aimmune Therapeutics Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Recent Operational Highlights". Brisbane, CA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top